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 Abstract 
 
Dissemination of HIV-1 throughout lymphoid tissues leads to systemic virus spread 
following infection. We combined tissue clearing, 3D-immunofluorescence, and electron 
tomography (ET) to longitudinally assess early HIV-1 spread in lymphoid tissues in 
humanized mice. Immunofluorescence revealed peak infection density in gut at 10-12 
days post-infection when blood viral loads were low. Human CD4+ T-cells and HIV-1–
infected cells localized predominantly to crypts and the lower third of intestinal villi. Free 
virions and infected cells were not readily detectable by ET at 5-days post-infection, 
whereas HIV-1–infected cells surrounded by pools of free virions were present in ~10% 
of intestinal crypts by 10-12 days. ET of spleen revealed thousands of virions released 
by individual cells and discreet cytoplasmic densities near sites of prolific virus 
production. These studies highlight the importance of multiscale imaging of HIV-1–
infected tissues and are adaptable to other animal models and human patient samples. 
 
 
Introduction 
HIV-1 presents an important global health issue with >36 million people infected 
worldwide and 2.1 million newly acquired infections in 2015. The majority of new HIV-1 
infections result from heterosexual transmission, with women accounting for a majority of 
all new infections worldwide (1). During heterosexual transmission of HIV-1, the virus 
crosses the genital epithelium and infects a target cell, which results in localized 
infection, establishment of a latently-infected virus reservoir, expansion of a local 
founder population, and systemic virus spread to distant tissues via lymph and blood (2). 
With blood containing only 1-2% of HIV-1 target cells in the body, the majority of HIV-1 
target cells in the human body reside within tissues (3, 4). Gut-associated lymphoid 
tissue (GALT), lymph nodes, and spleen contain a large number HIV-1 target cells that 
support localized virus transmission and remain a key source of virus replication during 
systemic spread and long term disease progression (5-7), yet the biological details of 
interactions between the virus and immune cells within tissues remain poorly 
characterized at single cell and subcellular resolution.  
 
HIV-1–infected animal models offer an opportunity to investigate virus spread within 
tissues using immunofluorescence (IF) and electron microscopy (EM) imaging. Model 
 systems of HIV-1 infection include both non-human primates (NHP) and mice, with 
mouse models being more practical for longitudinal studies of infection in which relatively 
large numbers of animals are infected. Mice with humanized immune systems (hu-mice) 
allow the rapid generation of human target cells infected with wildtype virus in a living 
organism with a functioning immune system and recapitulate important aspects of HIV-1 
pathology including mucosal infection, systemic virus spread, latency, and response to 
therapeutic intervention (8, 9).  
 
Optical clearing techniques, originally developed >100 years ago, enabled imaging of 
large volumes of tissue, which led to an enhanced understanding of human anatomy, but 
the original clearing methods are not compatible with modern fluorescence microscopy 
due to tissue destruction and quenching of the fluorescent signal (10-12). However, 
recent advances in optical clearing of intact tissues combined with 3D fluorescence 
microscopy enable imaging of tissues at single cell resolution (10, 12). The basic 
principles of tissue clearing involve removing opaque biomolecules that reduce light 
penetration into samples and matching the refractive index of optics, solutions, and 
tissues to minimize optical distortions during imaging. CLARITY/PACT and CUBIC 
tissue-clearing techniques were recently applied to render entire rodents optically clear 
while maintaining tissue integrity at the single cell level (13-17). When combined with IF 
and fluorescence microscopy, these techniques allow imaging of large volumes (mm3–
cm3) of intact tissues at single cell resolution, delineation of the connectivity of biological 
structures, and discrimination of individual cell types within complex tissue environments. 
Tissue clearing techniques were recently applied to image brain, nervous system, and 
internal organs in rodents, the spatial heterogeneity of mouse tumor models, 
developmental processes in zebrafish, and post-mortem pathology from preserved 
human samples (12-15, 18-20), but have not previously been used to image lymphoid 
tissues from HIV-1–infected animals.  
 
EM was originally utilized to identify HIV-1 as the causative agent of AIDS (21, 22) and 
has subsequently been applied to examine aspects of HIV-1 pathology at ultrastructural 
resolution (23). ET can provide 3D information at subcellular resolution from frozen 
hydrated or from well-preserved, fixed biological samples (24). ET of purified HIV-1 and 
HIV-1–infected cultured cells have contributed to our understanding of the HIV-1 life-
cycle through investigations of the structures of mature and immature virions (25-27), 
 envelope spike densities and conformations on virions (28, 29), virus biogenesis (30, 31), 
cell entry, and cell-to-cell transmission (32). Although informative, these studies provided 
no information concerning HIV-1 in the context of an infection within a host organism. 
The in situ environment involves multiple cell types within tissues and organs, which may 
alter virus behavior and fine-structural associations compared with infection within a 
cultured cell environment. In a previous study, we combined optimized tissue 
preservation methods with ET to image HIV-1 in GALT derived from chronically infected 
hu-mice (33). This approach allowed us to distinguish and characterize mature, 
immature, and budding virions, localize infected cells and intercellular pools of free 
virions within colon crypts, and identify distinct components of virus budding machinery 
within infected GALT tissues (33). These studies shed light on HIV-1 interactions during 
later phases of infection, establishing the groundwork for investigations of HIV-1 during 
critical early virus spread in lymphoid tissues. 
 
Here we address early HIV-1 spread by combining 3D-IF microscopy of optically-cleared 
tissues with ET of optimally-preserved tissues. This parallel approach allowed us to 
image systemic virus spread in HIV-1–infected hu-mouse lymphoid tissues at different 
volumes, resolutions, and times after infection. These analyses provided a longitudinal 
and spatial comparison of the location, type, and density of infected cells, routes of virus 
spread, and virus levels in lymphoid tissues. Infectivity in GALT and spleen preceded 
peak blood viremia and showed a rapid and exponential spread of virus in these tissues 
early after infection. Blood viral load peaked over a week later, when infectivity in several 
lymphoid tissues was beginning to diminish, emphasizing the discrepancy between 
blood and tissue infectivity. During times of peak infectivity, large numbers of free virions 
were identified in spleen, with individual infected cells being surrounded by >1,000 
virions within thin volumes of tissue. These studies provide multiscale information about 
the early systemic spread of virus within lymphoid tissues at both cellular and subcellular 
resolution, and these methods are readily adaptable to in situ analysis of HIV-1–infection 
in other hu-mouse and NHP models, and samples from human patients. 
 
Results 
 
Validation of PBMC-NSG hu-mouse model for imaging studies. 
 Perhaps the most accurate hu-mouse model, bone marrow/liver/thymus (BLT) mice, are 
generated by transferring CD34+ human stem cells together with human fetal thymic and 
liver tissues during individual surgeries into immunocompromised mice (34, 35). While 
BLT mice are optimal for studies of mucosal transmission of HIV-1 (36, 37), they are not 
cost effective for longitudinal studies of HIV-1 infection involving large cohorts of infected 
animals. We therefore used a technically simpler and less expensive hu-mouse model 
constructed by injection of primary human peripheral blood mononuclear 
cells/lymphocytes (PBMC/PBL) into NOD.Cg-PrkdscidIl2rgtm1Wjl/SzJ (NSG mice) (38-41), 
which are immunocompromised animals lacking mature natural killer cells, B-cells and 
T-cells. PBMC-NSG mice rapidly reconstitute human CD4+ and CD8+ T-cells in addition 
to human B-cells and disseminate human lymphoid cells to lymph nodes, spleen, bone 
marrow, genital mucosa, and intestine (8, 9, 38, 41, 42). It is important to note that the 
PBMC-NSG hu-mouse model almost exclusively harbors activated human T cells that 
can react with host antigens and cause animals to develop graph versus host disease 
(9). The lack of other cell lineages combined with raised levels of T cell activation in this 
model may enhance the dynamics of HIV spread and pathogenesis compared to other 
hu-mouse models that contain a smaller compartment of activated T cells at the time of 
infection and a more diverse set of immune cell lineages. Nonetheless, the robust 
reconstitution of activated human T-cells in the PBMC-NSG hu-mouse models is an 
important component for HIV-1 studies in hu-mice since (i) CD4+ T-cells make up the 
majority of all HIV-1 target cells in humans (5), (ii) activated T cells constitute a sizeable 
proportion of all CD4+ T cells in humans (~10%), (iii) activated T cells rise to ~20-40% 
during the course of HIV-1 infection (43), and (iv) activated T cells localize to important 
tissue sites of virus pathology including spleen, lymph nodes, and GALT (44, 45). 
Importantly, HIV-1 infection of PBMC-NSG mice mimics early stages of infection in 
humans, in that the virus replicates exponentially, resulting in large scale CD4+ T-cell 
depletion within a few weeks (9, 40, 46), and this model was previously used to study 
the effectiveness of anti-HIV-1 therapies in reducing systemic virus spread after 
intravenous transmission (40, 46-49). The lower cost, simplicity, rapid generation of HIV-
1–infected animal cohorts, and effective reconstitution of systemic virus spread make the 
PBMC-NSG hu-mouse model advantageous for longitudinal studies investigating early T 
cell-mediated pathogenic events in GALT, spleen, and peripheral blood.  
 
 HIV-1-infected PBMC-NSG mice normally show robust blood p24 levels ~2-4 weeks 
post-infection (PI), followed by a sharp decrease of viral load (40, 46-48). By contrast, 
blood p24 levels in HIV-1 infected BLT mice regularly peak at ~4-6 weeks PI, followed by 
a slower reduction in blood viral load (36, 50, 51). To compare with our previous imaging 
studies of GALT from long-term (10 to 20 weeks PI) infected BLT mice (33), we chose 3 
weeks PI for analysis and imaging in PBMC-NSG mice to ensure that human cells and 
virus would still be present in tissues. Female NSG mice were reconstituted with human 
PBMCs and three PBMC-NSG mice were infected with R5-tropic HIV-1 (pNL4-
3envYU2). HIV-1 p24 levels in blood showed mean levels of 2.50+/-0.78 ng/mL at 12 
days PI and 12.68+/-8.05 ng/mL at 21 days PI, demonstrating productive infection in all 
three animals (Fig. 1A). Infected animals were necropsied at 21 days PI, and adjacent 
GALT samples from the colon were fixed with aldehydes for parallel IF and ET analysis. 
IF of colon showed the presence of human CD3+ cells and HIV-1 p24 in infected 
animals 3 weeks PI in colon crypts and within the crypt epithelium (Fig. 1B). ET 
corroborated the IF results, showing the presence of infected cells indicated by virus 
budding profiles projecting from the plasma membrane and free virions in similar tissue 
locations (Fig. 1C, D). The localization and levels of T-cells and HIV-1 within colon crypts 
were consistent with our previous studies in HIV-1–infected BLT animals (33), 
establishing the validity of the PBMC-NSG model for conducting longitudinal imaging 
studies of HIV-1 infection and spread in lymphoid tissues. 
 
Tissue clearing and IF imaging of lymphoid tissues.  
We next sought to obtain spatial information about T-cell localization from multiple tissue 
types in PBMC-NSG mice. Optical clearing techniques offer the opportunity to image 
large volumes of opaque tissues by IF without serial sectioning (10). We used different 
methods for clarifying tissues: GALT and female reproductive tract (FRT) were cleared 
using CLARITY/PACT (16), and spleen samples containing heme were cleared using 
CUBIC (15) (Fig. 2A). Tissues from uninfected PBMC-NSG animals were 
immunostained and imaged by confocal microscopy using antibodies against human 
CD3 to evaluate T-cell reconstitution and against HIV-1 p24 to rule out background 
staining in uninfected animals. IF of cleared GALT from uninfected animals revealed 
human CD3+ T-cells in the colon, spleen, and FRT (Fig. 2B). These results established 
that optically cleared, intact lymphoid tissues from PBMC-NSG mice could be imaged by 
IF to detect the presence and localization of human T-cells. 
  
Lymphoid tissue samples from an acutely-infected animal with a high blood p24 level at 
21 days PI (10.85 ng/mL p24) were cleared and stained to visualize the distribution of 
human CD3+ T-cells and HIV-1. Confocal microscopy in different lymphoid tissues from 
HIV-1–infected PBMC-NSG mice revealed the presence of human CD3+ T-cells, a 
subset of which were positive for HIV-1 p24 (Fig. 2C). Some regions of p24 staining 
were not positive for human CD3, representing either free HIV-1 virions or infected cells 
other than T cells (Fig. 2C). 
 
Longitudinal quantification of GALT infectivity 
 
PBMC-NSG mice were infected and necropsied at specific times during the first 6 weeks 
PI (Fig. 3A), and lymphoid tissues were prepared for imaging studies as described 
above. Cleared colon samples from HIV-1–infected or mock-infected controls were 
immunostained and imaged (Fig. 3B). Representative images revealed low levels of 
infected human CD3+ T-cells at 5 days PI, which rapidly increased to peak levels at 10-
16 days PI, before diminishing at time points >21 days PI. To enable quantification of T-
cell and infection densities, the total number of nuclei in confocal slices were determined 
using the Fiji software suite (52), resulting in an agreement of 96.2+/-1.9% compared to 
manual quantification (Fig. 3-figure supplement 1). Human CD3+ T-cells from at least 
four confocal slices in 1-3 animals at individual time points were manually quantified in 
infected and uninfected controls (n>5000 cells per time point). T-cells in colon from 
uninfected PBMC-NSG mice remained near 6% of total cells (Fig. 3C), comparable to 
the ~10-12% found in uninfected human patient samples (53). Human CD3+ T-cell 
densities in HIV-1–infected animals were similar to densities in uninfected controls until 
12 days PI, at which time T-cell levels rapidly dropped to <4% of total cells at 16 days PI 
and continued to decrease gradually out to 45 days PI. p24+/human CD3+ T-cells were 
quantified similarly in GALT, revealing peak infectivity at 12 days PI, with nearly 3% of 
cells representing HIV-1–infected T-cells (Fig. 3D). Infectivity levels rapidly decreased to 
<1% of cells representing infected T-cells after 21 days PI and approached zero by 35 
days PI. When compared to p24 levels in blood from the same animals, the percent of 
p24+ T-cells peaked at 12 days PI and preceded peak blood p24 levels by 9 days, when 
p24 levels were low (Fig. 3D). At peak blood p24 levels (21 days PI), the percentage of 
p24+ T-cells in colon had already diminished to nearly half of maximum levels at 10-12 
 days PI. These results are consistent with a disconnect between tissue infectivity and 
blood viral load over time, as previously noted in human samples (54, 55). p24 not co-
localized with human CD3+ T-cells was compared to levels of p24 associated with 
human CD3+ T-cells (Fig. 3B, E). This analysis revealed an increase in p24 signal not 
associated with human CD3+ T-cells concomitant with decreased infectivity of human 
CD3+ T-cells at 21 days PI. 
 
Spatial and temporal distributions of HIV-1 in GALT 
Intact regions of HIV-1-infected GALT cleared and immunostained for human CD4+ T-
cells, human CD8+ T-cells, and HIV-1 p24 at specific times PI were imaged by confocal 
microscopy, and categories of cells in individual Z-slices were quantified (Fig. 4). A 45 
μm confocal Z-stack from the colon of an HIV-1–infected hu-mouse at 12 days PI 
displayed human CD4+ T-cells and p24+ cells localized to intestinal crypts and the 
bottom half of villi, whereas human CD8+ T-cells were dispersed uniformly throughout 
the crypts and the length of the villi (Fig. 4A, B and Movie 1). Mean distances from the 
base of crypts were 51.2 +/- 34.5 μm for human CD4+ T-cells, 79.2 +/- 36.8 μm for 
human CD8+ T-cells, and 47.9 +/- 45.1 μm for p24+ cells (Fig. 4C). The localization of 
HIV-1–infected cells to colon crypts is consistent with our previous EM and IF studies of 
later stages of HIV-1 infection in GALT from BLT hu-mice (33) and with results from 
early SIV infection in rhesus macaques (56). The spatial arrangement of these cell types 
remained constant during the course of the experiment (Fig. 4D), even as the total 
numbers of human CD4+ T-cells and p24+ cells markedly decreased at late time points 
(Fig. 4E), likely due to target cell depletion. 
 
ET of longitudinal HIV-1 spread in GALT 
To gain ultrastructural information about systemic virus spread in GALT, sections of HIV-
1–infected colon were imaged by EM at representative time points (Fig. 5A). Tissue 
samples adjacent to those used for IF were imaged in parallel by ET, as opposed to 
directly imaging the same tissue sample using both IF and EM, because the methods for 
extracting lipids from cleared tissues for IF eliminates scaffolding within the cell, resulting 
in destruction of ultrastructural details at the EM level (16). EM surveys of colon crypts, 
where we previously characterized active HIV-1 infection by ET in a BLT hu-mouse 
model (33), confirmed the infectious profile depicted by IF (Fig. 5A and B). Early after 
infection (5 days PI), infected cells and free virus were not readily detected. This was 
 followed by an exponential increase in the number of infected cells and the presence of 
large extracellular pools of free virus, often containing >100 free virions within 200-400 
nm thick regions of tissue during peak infectivity (10-16 days PI). At this time, ~10% of 
crypts showed signs of active infection cells as evidenced by cells with budding virions 
attached to the plasma membrane (Fig. 5B; center panel). At later times (>21 days PI), 
the total number of infected cells was reduced and individual pools of free virus in similar 
locations contained fewer virions. Most of the pools of free virus were not associated 
with actively-infected cells, consistent with our IF observation that levels of HIV-1 p24 
not associated with human CD3+ T-cells increased at later time points PI (Fig. 3B and 
E). These results suggested that most of the p24+/CD3- cells detected by IF at late 
times PI represented pools of free-virions, rather than infected cells other than T cells.  
 
A cross section of a colon villus highlighting a vascularized central channel of lamina 
propria from an HIV-1–infected hu-mouse 12 days PI revealed large pools of virus (Fig. 
5C; left and center panels). Pools of virus in lamina propria were often found near 
vasculature, and ET allowed tracing of a virus-containing lateral intercellular space in 3D 
exhibiting pools of virus with openings leading to the walls of blood vessels (Fig. 5C; 
right panels and Movie 2).  
 
Parallel IF and ET of HIV-1 Infection in Spleen 
We next imaged HIV-1 in spleen, first verifying that this organ in PBMC-NSG hu-mice 
exhibited characteristic architectural features. Splenic tissue can be histologically divided 
into regions of red and white pulp (57). Red pulp makes up a majority of the volume of 
the spleen, contains large numbers of red blood cells (RBCs) generating a red hue, and 
primarily functions to filter the blood. White pulp contains large numbers of B- and T-cells 
that coordinate immune responses within the blood. As such, spleen harbors large 
quantities of HIV-1 target cells, making it an important organ for HIV-1 pathology (57-59). 
Indeed, a longitudinal study of SIV infection in NHP spleen revealed large numbers of 
HIV-1–infected CD4+ T-cells during acute infection that resulted in T-cell depletion and 
morphological changes in tissue at later stages of infection (60), consistent with human 
autopsy studies (61). 
 
To determine if splenic tissue from hu-mice could be used to investigate HIV-1 infection, 
we imaged spleens from wildtype, NSG, and PBMC-NSG mice by brightfield, LM and 
 EM to determine levels of human T-cell reconstitution and compare splenic architectures 
(Fig. 6 and Fig. 6-figure supplement 1). Bright-field images of wildtype spleen showed 
the presence of round foci of white pulp separated by regions of red pulp (Fig. 6-figure 
supplement 1). EM of white pulp from wildtype animals revealed diverse cell types, 
including lymphocytes, and collagen deposits. In contrast, brightfied microscopy of 
spleen from non-reconstituted NSG animals showed little to no white pulp, and EM of 
these samples indicated different cell types, denser packing, and little collagen (Fig. 6-
figure supplement 1). Brightfield microscopy images of uninfected PBMC-NSG animals 
revealed regions of white pulp at greater levels than non-reconstituted NSG animals, but 
these were not organized into foci as in wildtype spleen. IF of uninfected PBMC-NSG 
spleen showed localized pockets of human CD3+ T-cells interspersed throughout 
volumes of splenic tissue (Fig. 2B and 6A; left panels). Montaged projection EM surveys 
of uninfected PBMC-NSG spleen demonstrated delineations between white pulp and red 
pulp regions (Fig. 6B; left panels and Fig. 6-figure supplement 1). Red pulp contained 
enucleated RBCs, while white pulp was distinguished by an absence of RBCs, bundles 
of collagen fibrils, and populations of lymphocytes identified as cells with large, dense 
nuclei surrounded by minimal cytoplasm. Overall, the organization of the spleen in 
PBMC-NSG hu-mice was intermediary between non-reconstituted NSG animals and 
wildtype immunocompetent animals, with white pulp occurring as smaller striations 
within the red pulp as opposed to the circular foci seen in spleens from wildtype animals 
(Fig. 6-figure supplement 1). These results demonstrated that structural and cellular 
components of splenic white pulp, most importantly HIV-1 target cells, are present in 
PBMC-NSG animals even though the splenic architecture is altered.  
 
To evaluate the distribution of virus and T-cells, adjacent samples of spleen from an 
HIV-1–infected PBMC-NSG animal at 12 days PI were imaged by IF and EM. IF of 
spleen revealed the presence of human CD3+ T-cells in addition to sporadic foci of HIV-
1 p24 distributed throughout large regions of tissue (Fig. 6A, right panels). EM of spleen 
from the same animal showed discernable regions of white pulp containing infected 
lymphocytes intercalated within bundles of collagen fibrils and surrounded by HIV-1 
virions (Fig. 6B; right panel and Fig. 7A, B; top panels). ET of an HIV-1–infected cell 
from spleen 12 days PI revealed prolific virus production at distinct regions of plasma 
membrane (Fig. 7A). Serial section tomographic reconstruction of a 6.9 μm x 3.5 μm x 
0.8 μm (19.3 μm3) volume from a single infected cell contained nearly 1,000 virus 
 particles of which 846 were mature, 18 were immature, and 102 were budding from the 
cell surface (Fig. 7A and Movie 3). By approximating the volume of an entire cell as an 
ellipsoid, we used this result to calculate that a single cell could produce >6,000 virions 
during a single round of virus production. A reconstructed 3.4 μm x 3.4 μm x 1.2 μm 
(13.9 μm3) volume from another HIV-1–infected cell in spleen at the same time PI 
revealed 1350 virus particles with 1329 mature, 15 immature, 6 budding virions, and 
predicted >4,000 virions released (Fig. 7B).  
 
HIV-1 budding machinery 
VPS4 is a hexameric AAA+ ATPase (62) recruited by the endosomal sorting complex 
required for transport (ESCRT) protein network to enable the fission of membranes 
during cellular processes including cell division, endosomal sorting, and virus budding 
(63). In previous ET studies of HIV-1 infection in GALT from BLT hu-mice, we identified 
discreet densities localized at the base of budding virions and proposed that they 
included VPS4 oligomers (33). We found similar densities localizing to the base of 
budding virions in tomograms of splenic tissue from HIV-1-infected PBMC-NSG mice at 
12 days PI (Fig. 8A). Immuno-EM using an anti-VPS4 antibody showed localization of 
VPS4 to the base of budding virions (Fig. 8B), demonstrating that VPS4 localizes to the 
same region, suggesting that the densities include VPS4, perhaps in complex with other 
proteins.  
 
In some cells, ET revealed large numbers of virions (>100 budding profiles) produced 
from distinct regions of the plasma membrane of HIV-1–infected cells (Fig. 8C). In the 
cytoplasm immediately adjacent to these sites of prolific virus release, we found 
accumulations of large numbers of densities indistinguishable from the densities near 
budding virions (Fig. 8C, D and 9). These cytoplasmic densities were found in direct 
proximity (within 1 µm of the plasma membrane) to large numbers of budding virions and 
contained hundreds to thousands of densities within an individual accumulation. As the 
cytoplasmic accumulations of these densities were rare, we were unable to prepare 
analogous negatively-stained samples for immuno-EM. However, we ruled out 
identification of the densities as ribosomes, since they were more electron dense than 
neighboring ribosomes and also lacked the characteristic cleft between the small and 
large ribosomal subunits (Fig. 9).  
 
 The cytoplasmic densities were not found in infected lymphocytes in the splenic white 
pulp that were surrounded by large pools of free virions but displayed few budding 
profiles (<10 buds); large cytoplasmic pools of density were absent in a cell that 
exhibited only 6 budding profiles (some of which also included the densities at the bases 
of the buds) but was surrounded by >1000 free extracellular virions (Fig. 8D). Indeed, 
accumulations of cytoplasmic densities were only seen in cells undergoing prolific virus 
budding, and in these cells, only in regions adjacent to the buds (Fig. 8D and Movie 4). 
These results suggest that cytoplasmic pools of these densities accumulate during 
periods of prolific virus production and are exhausted following a round of virus release.  
 
Discussion 
Here we combined tissue clearing, 3D-IF microscopy, and ET to longitudinally assess T-
cell systemic spread of HIV-1 in a hu-mouse model of HIV-1 infection at multiple levels 
of volume and resolution. Tissue clearing and IF microscopy allowed interrogation of 
volumes of intact tissues at single cell resolution. This approach provided information 
about the spatial distribution of human immune cells, HIV-1–infected cells, and virus 
proteins within multiple tissues from PBMC-NSG hu-mice at specific times after infection. 
ET of adjacent tissue regions allowed imaging at subcellular resolution and validated 
infectivity patterns identified by IF. These studies revealed a rapid and vast spread of 
virus throughout GALT and spleen at times when virus in blood was barely detectable.  
 
One focus of these studies was GALT, an important site for early aspects of HIV-1 
interaction with the immune system that is home to a large proportion of HIV-1 target 
cells and is critical for early establishment of HIV-1 infection and pathogenic effects that 
lead to long-term disease progression (3, 44, 45, 64, 65). Tissue clearing and 3D-IF 
allowed the quantification of human T-cells and HIV-1–infected cells within intact GALT 
from PBMC-NSG hu-mice (Fig. 3) and revealed a human CD3+ T-cell density that was 
comparable to those from human patient colon samples (53). Furthermore, human T-
cells were found in intestinal crypts, in agreement with results from HIV-1–infected colon 
samples from BLT hu-mice (33), colon samples from SIV-infected NHP (66), and 
uninfected human colon samples (53), validating the PBMC-NSG hu-mouse model for 
studying HIV-1 infection of human T-cells in GALT. Longitudinal quantification of 
infectivity in GALT revealed the dynamics of HIV-1 infectivity over time. Peak infectivity 
in GALT occurred while levels of virus in the blood, a hallmark of HIV-1 progression, 
 were quite low. GALT infectivity then rapidly decreased and coincided with a drop in 
human CD3+ T-cell density in HIV-1–infected animals (Fig. 3C, D), consistent with 
studies in humans showing T-cell depletion in GALT during acute HIV-1 infection (67, 
68). In our previous ET study of HIV-1-infection in GALT from BLT animals, all samples 
were from 10-20 weeks PI, yet HIV-1 and infected T cells were present (33). The more 
rapid dynamics of virus spread and target cell depletion in GALT of HIV-1–infected 
PBMC-NSG hu-mice could be due to the high levels of T cell activation and a lack of T 
cell replenishment in PBMC-NSG animals (9). 
 
In the colon of HIV-1–infected animals, human CD4+ T-cells preferentially localized to 
the bottom third of villi and in crypts whereas human CD8+ T-cells were more 
ubiquitously distributed (Fig. 4 and Movie 1). Accordingly, HIV-1–infected human CD4+ 
T-cells also localized to the bottom third of villi and in crypt regions, with most infected 
cells residing in crypts. This spatial distribution did not change over time, even as human 
CD4+/CD8+ T-cell ratios changed during the course of infection (Fig. 4D, E). These 
results suggest that local tissue environments influence cell localization and distribution 
within hu-mice; comparisons between other animal models and human patient samples 
will be required to extrapolate these findings. 
 
Adjacent sections of HIV-1–infected GALT were prepared for analysis by ET to gain 
ultrastructural information that focused on the establishment and spread of HIV-1 in 
lymphoid tissues. ET of GALT from HIV-1–infected PBMC-NSG hu-mice revealed few or 
no infected cells or virions at 5 days PI, peak infectivity at 10-16 days PI when infected 
cells and large pools of free virions were readily detectable, and reduced numbers of 
infected cells and sizes of virus pools at >21 days PI (Fig. 5). The ET results were 
consistent with our IF results and also agree with studies showing the establishment of 
SIV-infection in GALT and spleen early after infection (56, 60). 
 
Hundreds to thousands of free virions accumulating in pools near infected cells in both 
GALT and spleen were detected by ET (Fig. 5, 7 and Movie 2, 3), consistent with ET of 
GALT from HIV-1–infected BLT hu-mice (33). The highest levels of free virus in both 
GALT and spleen occurred at 10-12 days PI, a time when virus levels in the blood were 
low (Fig. 3). We detected pools of free virus contiguous with mucosal vasculature in 
GALT (Fig. 5), and in spleen, a tissue that acts to filter the blood, we visualized >1,000 
 virions being produced from one region of an HIV-1–infected cell (Fig. 7). We calculated 
that a single infected cell within tissue could produce >6,000 virions during a round of 
virus release, providing insights into the exponential production of HIV-1 within tissues 
early after infection. The total number of SIV virions produced by a single infected cell 
was previously estimated to be 4.0-5.4 x 104 (69). If a similar number of HIV-1 virions are 
produced from infected cells within tissue, this implies multiple rounds of virus release 
from each infected cell, as suggested by our previous ET studies (33). In tissues, the 
large numbers of target cells combined with high levels of virus production and 
accessibility to vasculature suggest that HIV-1–infected cells in tissue provide a source 
of free virus that contributes to blood viral load and systemic spread.   
 
We previously proposed that distinct densities observed at the base of budding virions 
during virus release contained VPS4 (33), an AAA+ ATPase recruited by polymerized 
ESCRT-III proteins that acts to recycle ESCRT-III in conjunction with abscission of the 
nascent virus membrane (63). Here we showed immuno-EM localization of anti-VPS4A 
antibodies to equivalent regions of budding virions (Fig. 8). In cells undergoing prolific 
budding, we found aggregations of hundreds to thousands of similar densities in 
adjacent regions of cytoplasm within close proximity (<1 μm) to budding virions (Fig. 8 
and Movie 4). Although we could not conclusively identify these densities as containing 
VPS4, they differed in size, intensity and shape from ribosomes, which are also 
distributed throughout the cytoplasm (Fig. 8, 9). Notably, the large accumulations of 
cytoplasmic densities were only present in cells undergoing prolific budding (>100 buds), 
suggesting they are directly involved in HIV-1 assembly and/or budding. Future immuno-
EM studies will be required to directly identify their components and involvement in the 
HIV-1 replication cycle. 
 
In summary, the parallel multiscale imaging approaches applied here allowed 
visualization of early HIV-1 spread in a hu-mouse model of infection at both single cell 
and subcellular resolution. 3D-IF of optically-cleared tissue allowed us to longitudinally 
and spatially interrogate the distribution of human T-cells and virus proteins within 
volumes of intact lymphoid tissue. ET of adjacent regions of tissue allowed the detection 
of individual virions, infected cells, and subcellular protein complexes within the context 
of actively-infected tissues at specific times PI. These approaches are directly applicable 
to additional lymphoid tissues such as lymph nodes, bone marrow, and thymus in 
 infected hu-mouse, NHP, and human patient samples. Future efforts will allow the direct 
spatial interrogation of biological processes occurring during early HIV-1 spread in 
lymphoid tissues and enable the development of a quantifiable spatial map of HIV-1 
spread in tissues during early infection. 
 
Methods  
 
Antibodies 
Primary antibodies for flow cytometry: mouse monoclonal anti-human CD3-FITC 
(Biolegend), mouse monoclonal anti-human CD4-PE (Biolegend), mouse monoclonal 
anti-human CD8 -APC (Biolegend). Primary antibodies for IF: rabbit polyclonal anti-
human CD3 (1:200; Dako), mouse monoclonal anti-HIV-1 p24 (1:200; Dako), rabbit 
polyclonal anti-HIV-1 p24 (1:200; gift of Wesley Sundquist, University of Utah), mouse 
monoclonal anti-human CD4-AlexaFluor 488 (1:50; Invitrogen), mouse monoclonal anti-
CD8-PE (1:100; Biolegend), rat anti-mouse CD16/32 (1:100; Biolegend), goat anti- 
collagen IV (1:250; Millipore). Secondary antibodies for IF: Alexa Fluor 488 goat anti-
rabbit IgG, Alexa Fluor 546 goat anti-rabbit IgG, Alexa Fluor 647 goat anti-rabbit IgG, 
Alexa Fluor 488 goat anti-mouse IgG, Alexa Fluor 546 goat anti-mouse IgG, Alexa Fluor 
647 goat anti-mouse IgG, Alexa Fluor 488 donkey anti-goat IgG, Alexa Fluor 546 donkey 
anti-goat IgG, and Alexa Fluor 647 donkey anti-goat IgG (Invitrogen). All secondary 
antibodies were used at 1:1000. For immuno-EM, rabbit monoclonal anti-VPS4A 
(AbCam) was used at a dilution of 1:500 and 10 nm gold-conjugated goat anti-rabbit IgG 
(Ted Pella) was used at a dilution of 1:20. 
 
Flow Cytometry of primary and reconstituted human PBMCs 
Cultured human PBMCs (AllCells, inc.) were analyzed by flow cytometry (MACSquant) 
to verify the presence of T-cell populations as described (47) using antibodies against 
human CD3, CD4, and CD8. Lymphocyte populations were identified by forward and 
side-scatter profiles and human T-cells were identified by human CD3 staining. Gated 
human CD3+ T-cell subsets were evaluated for the presence of human CD4 and CD8 T-
cells.  Mouse whole blood samples were treated with RBC lysis/fixation solution 
(Biolegend) prior to immunostaining and analysis by flow cytometry as described for 
cultured huPBMCs. 
 
 Humanization and HIV-1 infection of immune deficient mice 
NOD.Cg-PrkdscidIl2rgtm1Wjl/SzJ (NOD/SCID/IL2Rγ−/− or NSG); The Jackson Laboratory) 
mice were reconstituted with human PBMCs as previously described (46, 47, 70). 
Briefly, primary human PBMCs (AllCells, inc.) were cultured for 13 days in RPMI 
simultaneously supplemented with human IL-2 (R&D Biosystems) and continually 
stimulated with phytohemagglutinin-P (Sigma). 2-5 x 106 cells were injected 
intraperitoneally into each animal. Reconstituted animals were retro-orbitally infected 
with 25 ng R5-tropic HIV-1 (pNL4-3 backbone pseudotyped with a YU2 envelope 
obtained from Michel Nussenzweig, Rockefeller University) 4 weeks later. Infection was 
monitored by weekly blood draw and upon sacrifice. Blood samples were inactivated 
with 4% Triton X100 for 1 hr at 37 C, and p24 levels were quantified by ELISA (Cell 
Biolabs). Assuming 2000 molecules of p24 per virion, and a molecular weight of 24 kDa, 
there are ~107 HIV virions per nanogram of p24 
(http://tronolab.epfl.ch/webdav/site/tronolab/shared/protocols/TUvsp24.html). Animals 
were sacrificed by CO2 inhalation followed by cervical dislocation and necropsied. 
Lymphoid tissues were excised and immediately placed into cacodylate buffer 
containing 5% sucrose (Sigma) and 0.1 M sodium cacodylate trihydrate (Sigma) with 
freshly added 8% paraformaldehyde (Electron Microscopy Sciences). Samples were 
stored in fixative at 4˚C until processed for LM, EM, or immuno-EM. All animal 
experiments were approved by the Caltech IACUC. 
 
Tissue clearing  
GALT and FRT samples were cleared using the CLARITY/PACT method adapted from 
(16). Fixed tissue regions were washed 3x in PBS for 30 minutes each and incubated at 
4°C overnight in a hydrogel monomer solution of 10% acrylamide in PBS supplemented 
with 0.25% photoinitiator VA-044 (2,20 -Azobis[2-(2-imidazolin-2-yl) propane] 
dihydrochloride; Fischer). Tissue samples were warmed to room temperature, incubated 
for 1-3 hours at 37°C, and monitored for hydrogel polymerization as indicated by a rapid 
increase in solution viscosity. Samples were immediately placed into PBS and washed 
3x over the course of several hours. Tissue samples in hydrogel were placed into conical 
tubes containing 8% SDS in PBS and incubated for 2-7 days at 37°C with shaking. SDS 
was exchanged daily until samples appeared visually transparent. Cleared tissue 
hydrogel samples were washed 5x in PBS over one day and stored in the dark in PBS at 
room temperature for up to 6 months. 
  
Spleen sample were cleared using the CUBIC method adapted from (14). Fixed tissue 
samples were washed in PBS as described above, placed into CUBIC-1 solution (25% 
w/v urea, 25 w/v N,N,N’,N’-tetrakis (2-hydroxypropyl) ethylenediamine (Sigma), 15% w/v 
polyethylene glycol mono-p-isooctylphenyl ether/Triton X-100 (Sigma), and incubated at 
37°C with gentle agitation. CUBIC-1 solution was exchanged daily for 3-7 days until 
tissue was adequately decolorized. Samples were then washed 5x in PBS over one day, 
transferred into CUBIC-2 solution (50% w/v sucrose, 25% w/v urea, 10% w/v 2,2,2’-
nitrilotriethanol (Sigma), and 0.1% (v/v) Triton X-100), and incubated at 37°C with gentle 
agitation. CUBIC-2 solution was exchanged daily for 5-10 days until the tissue appeared 
visually transparent. CUBIC-2–treated tissue samples were washed 5x in PBS over one 
day and either immediately immunostained, stored for up to 6 months in PBS at room 
temperature in the dark, or frozen and stored long term in optimal cutting temperature 
compound (Sakura Finetek) at -80°C. 
 
Immunostaining  
Cleared tissue samples were incubated in blocking buffer (2-4% FBS, 0.1% Tween-20 or 
Triton X-100, 0.01% NaN3) overnight at 4°C. For samples that were immunostained with 
mouse monoclonal antibodies, rat anti-mouse CD16/32 (Biolegend) was added to 
blocking buffer (1:50) to reduce background. Primary antibody staining was conducted in 
blocking buffer containing primary antibodies for 2-3 days. Tissue samples were washed 
5x over one day with wash solution (0.1% Tween-20 or Triton X-100, 0.01% NaN3 in 
PBS). Samples were then incubated with secondary antibody (1:1000) in blocking buffer 
for 2 days and washed 5x over one day in wash solution. To stain for nuclei, washed 
tissue samples were incubated in 1 g/mL 4',6-diamidino-2-phenylindole (DAPI) in PBS 
for 8 minutes. Samples were washed 3x for 10 minutes in PBS and incubated overnight 
in refractive index matching solution (RIMS) containing 90% Histodenz (Sigma) in 0.02M 
NaPO4 (Sigma) pH 7.5 buffer supplemented with 0.1% Tween-20 and 0.01% NaN3 
(Sigma) for CLARITY/PACT-cleared tissues or CUBIC-2 solution for CUBIC-cleared 
tissues. All staining and incubations were performed at room temperature with gentle 
rocking and kept in the dark after the addition of fluorescent-labeled antibodies.  
 
Confocal IF Microscopy and image analysis 
 Samples were mounted between two No.1 coverslips (Electron Microscopy Sciences) 
separated by adhesive/adhesive silicone isolators (Electron Microscopy Sciences) in 
RIMS for CLARITY samples or CUBIC-2 solution for CUBIC samples. Mounted samples 
were imaged with a Zeiss LSM-710 or 880 using a LD LCI Plan-Apochromat 25× 0.8 NA 
Imm Corr DIC M27 multi-immersion objective (w.d. 0.57 mm) with glycerol. Images were 
analyzed with the Fiji software suite (52). Images were smoothed and individually 
thresholded to minimize background tissue autofluorescence. Nuclei were quantified by 
thresholding the DAPI channel to show individual nuclei. Images were smoothed, made 
binary, and particles >2 μm were analyzed after overlapping nuclei were separated using 
the watershed function. Automated nuclei quantification was compared against 4 manual 
counts with >650 individual nuclei per field of view. 3D movies of confocal Z-stacks were 
made with the Imaris software suite. Gamma levels for DAPI staining were thresholded 
to emphasize CD4, CD8, and p24 cell staining throughout the volume. 
 
Brightfield Imaging  
Fixed spleen tissues were also used for brightfield imaging. Large slices (~2 mm x 3 mm 
by x 0.5 mm) of tissue were cut with a microsurgical scalpel and placed on glass slides. 
Specimens were imaged with a Diaphot-200 microscope (Nikon, Inc.) using a 4x 
objective lens in brightfield mode. Images were recorded digitally. 
 
EM Sample Preparation 
Prefixed lymphoid tissues (described above) were prepared for EM as previously 
described (33). Briefly, samples were rinsed in cacodylate buffer and trimmed to <~1 
mm3 blocks. One to three tissue blocks were placed into brass freezing planchettes (Ted 
Pella, Inc.) prefilled with cacodylate buffer containing 10% Ficoll (Sigma). Samples were 
rapidly frozen in a HPM-010 high pressure freezer (Leica Microsystems) and transferred 
to liquid nitrogen. The planchettes were placed under liquid nitrogen into cryo tubes 
(Nunc) containing 2 ml of 2.5% OsO4, 0.05% uranyl acetate in acetone, and then 
transferred to a AFS2 freeze-substitution machine (Leica Microsystems). Samples were 
freeze substituted for 72 hours at -90°C and then warmed to -20°C over 12 hours. After 
24 hr at -20°C, the samples were warmed to room temperature, rinsed with acetone, and 
infiltrated with Epon-Araldite resin (Electron Microscopy Sciences). Tissue pieces were 
flat embedded between two Teflon-coated glass slides and polymerized at 60°C for 48 
hr.  
 Embedded tissue samples were selected and sectioned as previously described (33). 
400 nm sections were cut with a UC6 ultramicrotome (Leica Microsystems) using a 
diamond knife (Diatome, Ltd.) and placed on Formvar-coated copper-rhodium 1 mm slot 
grids (Electron Microscopy Sciences). Sections were stained with 3% uranyl acetate and 
lead citrate. Colloidal gold particles (10 nm) were placed on both surfaces of the grids as 
fiducial markers. Grids were stabilized with evaporated carbon prior to imaging.  
 
Electron tomography 
Grids were placed in a Dual-Axis Tomography holder (Fischione Instruments, Inc.) and 
imaged with a Tecnai TF30ST-FEG microscope (FEI) at 300 KeV. Dual-axis tilt series 
(+/-64°; 1° intervals) were acquired automatically using SerialEM software (71). 
Tomographic data were aligned, analyzed and segmented using IMOD (72) on MacPro 
computers. 
Immuno-EM 
Prefixed lymphoid tissues were cut into ~1 mm3 blocks and infiltrated with 2.1 M sucrose 
in cacodylate buffer over 10 hours. Blocks were affixed to aluminum sectioning stubs 
and frozen in liquid nitrogen. Cryosections (100 nm) were cut with a UC6/FC6 
cryoultramicrotome using a Cryo-Immuno diamond knife (Diatome, Ltd), transferred in a 
wire loop containing a drop of 2.3 M sucrose in PBS to Formvar-coated, carbon-coated, 
glow- discharged 100-mesh copper/rhodium grids, warmed to room temperature, labeled 
with primary and colloidal gold secondary antibodies, negatively stained, and embedded 
with 1% uranyl acetate, 1% methylcellulose in dH2O. Stained grids were air-dried in wire 
loops overnight.  
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 Figures and Movies 
 
Figure 1. HIV-1 infection and Imaging of hu-mice 
(A) Mean blood p24 levels from three HIV-1–infected PBMC-NSG mice assessed at 0, 
12, and 21 days PI. Error bars represent standard deviation. (B) IF of GALT from HIV-
infected animal with highest blood p24 level from panel A at 21 days PI. Samples were 
stained for human CD3 (magenta), HIV-1 p24 (green), and nuclei (blue). White arrows 
indicate human CD3+/p24+ cells. (C) Montaged projection EM overview of colon crypt 
region from the same animal. Areas with virus are highlighted (green asterisks) along 
with a region of interest for imaging by ET (yellow box). Virus was found in close 
proximity to a blood vessel (BV) containing red blood cells (RBCs). (D) Tomographic 
slice of region of interest from panel C showing separate pools of free virus on two sides 
of an infected cell. Black arrows indicate budding virions. 
  
Figure 2. Tissue clearing and IF imaging of lymphoid tissues  
(A) Representative images of uncleared (left) and cleared (right) lymphoid tissues from 
uninfected hu-mice. (B, C) Confocal images of cleared lymphoid tissues from uninfected 
(panel B) and HIV-1–infected (21 days PI) (panel C) hu-mice stained with antibodies 
against human CD3 (magenta) and HIV-1 p24 (green). Nuclei were labeled with DAPI 
(blue). Scale bars for overview images = 50 μm. Scale bars for zoomed views = 20 μm. 
 
  
Figure 3. Longitudinal quantification of GALT infectivity 
(A) Timeline of immune cell reconstitution, HIV-1 infection, and tissue harvest from hu-
mice. Top numbers depict days PI, bottom numbers show number of animals per 
timepoint. Single uninfected animals were sacrificed at 0, 21, and 45 days PI. All other 
animals were infected and sacrificed at the times indicated. (B) Representative images 
showing human CD3+ T-cells (magenta), HIV-1 p24 (green), and nuclei (blue) in colon at 
early (0-5-days PI), peak (10-16 days PI), and late (>21-days PI) infectivity. Arrows 
indicate infected cells. Asterisks show p24 not associated with human CD3+ T-cells. (C-
E) Error bars represent standard deviation. n > 5,000 cells from 1-3 animals for all time 
points. (C) Quantification of human CD3+ T-cells as the percent of total cells for HIV-1–
infected (black line) or uninfected (gray line) animals. (D) Comparison of GALT infectivity 
as percent infected cells of total (black line, left Y-axis) with blood p24 (gray line, right Y-
 axis, ng/mL) levels over time. (E) Longitudinal profile of percent HIV-1 p24-positive 
human CD3+ T-cells (black line, left Y-axis) and percent of p24 signal not associated 
with human CD3+ T-cells (gray line, right Y-axis).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 3-figure supplement 1. Validation of automated quantification of 
nuclei 
(A) Representative confocal slice of colon sample. Nuclei are white. 881 nuclei 
were manually counted. (B) Automated quantification of the image shown in 
panel A resulting in 842 nuclei. Low numbers in blue that progress to white for 
higher numbers. (C) Plots of total number of nuclei counted manually or 
computationally for four separate confocal slices. (D) Percent accuracy between 
manual and automated quantification for each image. 
 
 
 
 
  
Figure 4. Spatial distribution of HIV-1 infection in GALT over time 
(A) Representative confocal slice from 45 μm Z-stack depicting the distribution of human 
CD4+ T-cells (magenta), HIV-1 p24 (green), human CD8+ T-cells (red) and nuclei (blue) 
in colon at 12-days PI. (B) Zoom of boxed region in panel A showing individual channels 
and merged view for human CD4+ T-cells, human CD8+ T-cells, and p24. (C-E) Error 
bars represent standard deviation. (C) Quantification of Z-stack from panel A showing 
the distance (μm) from the base of crypts of human CD4+ T-cells (magenta), human 
 CD8+ T-cells (red), and p24+ T-cells (green) for the volume in panel A. * indicates 
p<0.0001 (two-tailed). (D) Quantification of distance (μm) from the base of crypts for 
human CD4+ T-cells (magenta), human CD8+ T-cells (red), and p24+ T-cells (green) for 
individual volumes during times of early, peak, and late infectivity. n > 2,000 total cells 
for each volume. (E) Quantification of CD4+ T-cells (magenta), human CD8+ T-cells 
(red), and p24+ T-cells (green) as a percentage of total cells at early, peak, and late 
infectivity times. n > 5000 total cells for each time point. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 5. Electron tomography of longitudinal HIV-1 spread in GALT 
(A, B) Montaged overview EM projection images (panel A) and zoomed tomographic 
slices (panel B) of HIV-1–infected colon crypts from hu-mice from early (5 days), peak 
(10-16 days), and late (>21-days) time points PI. Arrows indicate pools of free virions 
between cells. (C) Lamina propria from HIV-1 infected GALT 10 days PI. Left: montaged 
 overview EM projection image showing lamina propria in cross-section. Arrows indicate 
blood vessels containing red blood cells. Yellow box indicates zoomed region of interest 
depicted in middle panel. Zoomed region from overview reveals pools of virus adjacent 
to vasculature. Right: tomographic slices of two indicated regions (arrows) that reveal 
pools of virus contiguous with blood vessel walls connected by lateral intercellular space. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
  
Figure 6. Parallel IF and ET of HIV-1 infection in spleen 
(A) Confocal IF images of cleared spleen showing human CD3+ T-cells (magenta), HIV-
1 p24 (green), and nuclei (blue) from an uninfected (-HIV) or infected (+HIV) animal at 
12-days PI. Yellow boxes indicate areas of zoomed views. White arrows indicate regions 
with p24. (B) Montaged overview EM projection images from adjacent regions of spleen 
from the same animals in A. Yellow dashed lines depict regions of white pulp, black 
arrows indicate red blood cells in a region of red pulp, white arrowhead shows an HIV-1-
infected cell.  
 
 
 
 
 
 
 
 
 
 
 
 Figure 6-figure supplement 1. Architecture of the spleen in wildtype, NSG, and 
PBMC-NSG mice.  
 Bright-field microscopy images (left panels) of sections of fixed spleen from wildtype, 
NSG, PBMC-NSG, and HIV-1–infected PBMC-NSG mice. White pulp and red pulp are 
lighter colored and dark red regions, respectively. HIV-1–infected and uninfected PBMC-
NSG animals displayed an intermediate level and organization of white pulp compared 
to wildtype and NSG animals of the same genetic background. EM images (right panels) 
from lighter colored white pulp regions of spleen from animals show in left panels. Red 
blood cells (black arrows) and collagen (white arrows) were identified in all samples. 
Wildtype spleen contained a greater variety of cell types and more collagen (white 
arrows) than NSG spleens, which were nearly devoid of white pulp and collagen. 
Uninfected and HIV-1–infected PBMC-NSG spleens revealed the presence of collagen 
and numerous cell types within regions of white pulp. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 7. ET and modeling of HIV-1 Infection in spleen 
(A and B) EM projection images of HIV-1-infected cells from regions of spleen from an 
HIV-1-infected animal 12-days PI (top panels). Collagen fibrils (white arrows) and pools 
of virions (black arrows) surround the infected cells. Yellow boxes indicate regions of 
tomographic reconstruction. Tomographic slices show zoomed detail of infected cells 
(middle panels). Modeled mature (green), immature (blue), and budding (magenta) 
virions from the full volume of tomographic reconstructions (bottom panels). Scale bars 
for tomogram and model panels are 0.5 m. 
 
 Figure 8. Localization of HIV-1 budding machinery    
 (A) Densities localized to the base of budding virions. (B) Anti-VPS4A immuno-EM 
revealing localization patterns consistent with densities in panel A. (C) Tomographic 
slice of HIV-1–infected spleen 12 days PI showing large accumulations of densities 
(black arrows) adjacent to regions of prolific virus release. (D) Tomographic slices 
showing budding virions from the animal in panel C revealing prolific budding (left) or low 
levels of budding (right). Arrowheads indicate budding virions and arrows indicate 
densities. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 9. Comparison of virion-associated densities, cytoplasmic densities, and 
densities corresponding to cytoplasmic ribosomes  
(A) Representative tomographic slices of densities associated with budding virions (top), 
cytoplasmic pools near budding virions (middle), and cytoplasmic ribosomes. (B) Gallery 
of images with the same tomographic thickness (9.1 nm) for individual densities 
associated with budding virions (top), cytoplasmic pools near budding virions (middle), 
and cytoplasmic ribosomes. Dimensions of virion-associated and cytoplasmic densities 
were indistinguishable. Ribosomes contain a visible cleft between individual subunits 
that is absent in the densities associated with budding virions and cytoplasmic pools 
near areas of prolific virus production. 
  
 Movie Legends 
 
Movie 1. Spatial Distribution of HIV-1 and T-cells in GALT 
360˚ rotation of a 45 μm thick Z-stack depicting the spatial distribution of human CD4+ 
T-cells (magenta), HIV-1 p24 (green), human CD8+ T-cells (red) and nuclei (blue) in 
colon at 12-days PI. Crypts are at the base and villus tips extend toward the top of the 
volume. Quantification of this volume is reported in Fig. 4A-C.   
 
Movie 2. ET of a pool of virions in GALT at peak infectivity 
Tomographic reconstruction of a volume of two consecutive 400 nm serial sections from 
colon of a PBMC-NSG animal 10-days PI (Fig. 5C, upper right panel). A pool of virions 
resides in the center with the lateral intercellular space between two cells extending into 
the upper right portion of the movie and is contiguous with a blood vessel wall (Fig. 5C, 
center panel). Scale bar = 0.5 μm. 
 
Movie 3. Modeling of an infected cell and individual virions in spleen  
Tomographic reconstruction of a volume of two consecutive 400 nm serial sections of an 
HIV-1–infected cell from spleen of a PBMC-NSG animal 12-days PI. Virions are modeled 
as mature (green), immature (blue), and budding (magenta). Coiled fibrils of collagen are 
evident surrounding the periphery of the cell and free virions. The second half of the 
movie shows zoomed detail. Scale bar = 1 μm. 
 
Movie 4. ET of densities associated with virus budding 
Tomographic reconstruction of an accumulation of cytoplasmic densities associated with 
prolific virus release. Densities were present in cytoplasm immediately adjacent to a 
region of plasma membrane supporting prolific virus release and at the base of budding 
virions. Scale bar = 0.2 μm. 
 
 
